Exposure of patients to di(2-ethylhexy)phthalate (DEHP) and its metabolite MEHP during extracorporeal membrane oxygenation (ECMO) therapy.

ABSTRACT: The plasticizer di(2-ethylhexyl)phthalate (DEHP) is often used for PVC medical devices, that are also largely used for intensive care medical treatments, like extracorporeal membrane oxygenation (ECMO) therapy. Due to the toxicological potential of DEHP, the inner exposure of patients with this plasticizer is a strong matter of concern as many studies have shown a high leaching potential of DEHP into blood. In this study, the inner DEHP exposure of patients undergoing ECMO treatment was investigated. The determined DEHP blood levels of ECMO patients and the patients of the control group ranged from 31.5 to 1009 ?g/L (median 156.0 ?g/L) and from 19.4 to 75.3 ?g/L (median 36.4 ?g/L), respectively. MEHP blood levels were determined to range from < LOD to 475 ?g/L (median 15.9 ?g/L) in ECMO patients and from < LOD to 9.9 ?g/L (median 3.7 ?g/L) in the control group patients, respectively. Increased DEHP exposure was associated with the number of cannulas and membranes of the ECMO setting, whereas residual diuresis decreased the exposure. Due to the suspected toxicological potential of DEHP, its use in medical devices should be further investigated, in particular for ICU patients with long-term exposure to PVC, like in ECMO therapy.

SUBMITTER: Kaestner F 

PROVIDER: S-EPMC6992201 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature